Bando, Hideaki

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Kotani, D., Oki, E., Nakamura, Y., Yukami, H., Mishima, S., Bando, H., Shirasu, H., Yamazaki, K., Watanabe, J., Kotaka, M., et al. (2023) · Nature Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 526

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., et al. (2020) · Nature Medicine

Cancer Genomics and DiagnosticsColorectal Cancer Treatments and Studies

Cited by 373

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

Shinozaki, E., Yoshino, T., Yamazaki, K., Muro, K., Yamaguchi, K., Nishina, T., Yuki, S., Shitara, K., Bando, H., Mimaki, S., et al. (2017) · British Journal of Cancer

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 65

Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy

Osumi, H., Shinozaki, E., Nakamura, Y., Esaki, T., Yasui, H., Taniguchi, H., Satake, H., Sunakawa, Y., Komatsu, Y., Kagawa, Y., et al. (2024) · Nature Communications

Colorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics

Cited by 17

Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2 -Amplified Metastatic Colorectal Cancer

Iida, N., Imai, M., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., et al. (2024) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies

Cited by 2